AstraZeneca plc (LON:AZN) Earns “Neutral” Rating from BNP Paribas
Other equities analysts have also issued research reports about the stock. UBS AG set a GBX 5,150 ($67.25) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Wednesday, April 5th. HSBC Holdings plc reissued a reduce rating and issued a GBX 4,200 ($54.84) price target on shares of AstraZeneca plc in a report on Friday, May 5th. Shore Capital reissued a sell rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. J P Morgan Chase & Co reissued a neutral rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Finally, Berenberg Bank boosted their price target on shares of AstraZeneca plc from GBX 5,670 ($74.04) to GBX 5,850 ($76.39) and gave the company a buy rating in a report on Wednesday, May 17th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. AstraZeneca plc presently has a consensus rating of Hold and a consensus price target of GBX 5,251.80 ($68.58).
Shares of AstraZeneca plc (LON:AZN) opened at 5075.00 on Friday. The stock has a 50 day moving average price of GBX 5,235.89 and a 200 day moving average price of GBX 4,847.81. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 64.25 billion.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/07/24/astrazeneca-plc-lonazn-earns-neutral-rating-from-bnp-paribas.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.